A Model to Predict Risk of Hyperkalemia in Patients with Chronic Kidney Disease Using a Large Administrative Claims Database
Ajay Sharma,1 Paula J Alvarez,2 Steven D Woods,2 Dingwei Dai1 1Healthagen, An Affiliate of Aetna Inc., A Part of the CVS Health Family of Companies, New York, NY, USA; 2Managed Care Health Outcomes, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USACorrespondence: Dingwei DaiHealthag...
Main Authors: | Sharma A, Alvarez PJ, Woods SD, Dai D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-11-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/a-model-to-predict-risk-of-hyperkalemia-in-patients-with-chronic-kidne-peer-reviewed-article-CEOR |
Similar Items
-
Hyperkalemia and chronic kidney disease
by: S.V. Kushnirenko
Published: (2019-02-01) -
Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options
by: Enrique Morales, et al.
Published: (2021-06-01) -
Hyperkalemia in heart failure patients: current challenges and future prospects
by: López-Vilella R, et al.
Published: (2016-02-01) -
The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
by: Daniel Murphy, et al.
Published: (2021-07-01) -
Hyperkalemia - a review article
by: Marcin Makuch, et al.
Published: (2019-07-01)